GlassScriptPhysician profile
Michelle A Digiovanni
NPI 1891932703
$1,742.58
in general payments reported to CMS, 2019-2025
36 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.00 · 2022: $332 · 2023: $688 · 2024: $267 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.21 |
| Education | $280.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $205.78 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.78 | 2022-2024 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $177.84 | 2023-2025 | Fotivda |
| Amgen INC. | $146.53 | 2022-2023 | Kyprolis, Nplate, Xgeva |
| Novartis Pharmaceuticals Corporation | $90.85 | 2023-2025 | |
| Genzyme Corporation | $64.61 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $62.98 | 2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $59.83 | 2023-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $54.25 | 2022-2023 | Opdivo |
| Janssen Biotech, INC. | $49.10 | 2024-2025 | Rybrevant |
| Celgene Corporation | $48.22 | 2024-2025 | Pomalyst, Reblozyl |
| Ipsen Biopharmaceuticals, INC | $42.64 | 2023-2025 | Tazverik, Onivyde |
| Siemens Medical Solutions USA, INC. | $42.15 | 2023 | Aria Radiation Therapy Management Software |
| Mirati Therapeutics, INC. | $32.45 | 2023 | Krazati |
| Geron Corporation | $29.99 | 2025 | Rytelo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $29.64 | 2025 | |
| Lilly USA, LLC | $28.19 | 2025 | Verzenio |
| Karyopharm Therapeutics INC. | $23.40 | 2022 | |
| Sumitomo Pharma America, INC. | $23.36 | 2023 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2023 | |
| Acrotech Biopharma INC. | $22.07 | 2023 | Beleodaq |
| Genentech USA, INC. | $22.05 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.97 | 2022 | |
| Sobi, INC | $21.58 | 2022 | |
| Abbvie INC. | $21.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.67 | 2023 | |
| Cti Biopharma Corp. | $20.67 | 2023 | Vonjo |
| Stemline Therapeutics INC. | $20.44 | 2025 | Orserdu |
| Incyte Corporation | $20.37 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.88 | 2025 | Romvimza, Qinlock |
| Napo Pharmaceuticals INC | $18.29 | 2024 | Gelclair Concentrated Oral Gel |
| Regeneron Healthcare Solutions, INC. | $17.92 | 2025 | Libtayo |
| Beigene USA, INC. | $17.91 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $17.67 | 2025 | Datroway |
| Astrazeneca Pharmaceuticals LP | $15.64 | 2023 | Lynparza |
| Novocure INC. | $15.20 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Digiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.